Trastuzumab (also called Herceptin), a humanized mAb, was the first GFR‐targeted drug to be introduced into oncology and is routinely used to treat breast cancers overexpressing the EGFR family member HER2 (human epidermal growth factor receptor 2, also called ErbB2).53 This evidence concerns the gene ERBB2 and breast cancer.